Memorial Sloan Kettering Cancer Center (MSK) is a free-standing NCI-designated Comprehensive Cancer Center dedicated to improving the standards of cancer treatment, prevention and control. MSK?s research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Structural and Chemical Biology); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Population Science Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators. MSK seeks to encourage the application of scientific discoveries in a way that advances the prevention, detection, diagnosis, and treatment of the many forms of cancer that are relevant to the population in our catchment area. Scientific work in the 10 research programs depends on services provided by 26 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 20 of these core facilities. Over the next five years, MSK will continue to enhance its clinical and research facilities and its research and training programs in emerging research areas. Support is requested to provide developmental funding for the support of newly recruited investigators in computational biology, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.
Memorial Sloan Kettering Cancer Center (MSK) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities. Through these activities, MSK seeks to reduce the burden of cancer throughout our catchment area and the nation.
|Barzilai, Ori; DiStefano, Natalie; Lis, Eric et al. (2018) Safety and utility of kyphoplasty prior to spine stereotactic radiosurgery for metastatic tumors: a clinical and dosimetric analysis. J Neurosurg Spine 28:72-78|
|Rosenberg, Jonathan B; Kaplitt, Michael G; De, Bishnu P et al. (2018) AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Hum Gene Ther Clin Dev 29:24-47|
|Ma, Jennifer; Lok, Benjamin H; Zong, Jingfeng et al. (2018) Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. Int J Part Ther 4:10-19|
|Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:|
|Garg, Angad; Goldgur, Yehuda; Schwer, Beate et al. (2018) Distinctive structural basis for DNA recognition by the fission yeast Zn2Cys6 transcription factor Pho7 and its role in phosphate homeostasis. Nucleic Acids Res 46:11262-11273|
|Scordo, Michael; Shah, Gunjan L; Kosuri, Satyajit et al. (2018) Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 24:133-141|
|Wei, Iris H; Garcia-Aguilar, Julio (2018) Non-operative management of rectal cancer: understanding tumor biology. Minerva Chir 73:601-618|
|Murali, Rajmohan; Grisham, Rachel N; Soslow, Robert A (2018) The roles of pathology in targeted therapy of women with gynecologic cancers. Gynecol Oncol 148:213-221|
|Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428|
|Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2018) Truncated ?-Opioid Receptors With 6 Transmembrane Domains Are Essential for Opioid Analgesia. Anesth Analg 126:1050-1057|
Showing the most recent 10 out of 8799 publications